Over the past three decades, within the realm of solid tumors exemplified by gastric cancer and breast cancer, HER2 has emerged as a key target for novel drugs, including tyrosine-kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), and dual-antibody agents. Here, ERBB2 is linked to breast carcinoma.